Alkem Laboratories Ltd. Share Price

ALKEM LABORATORIES SHARES SLIP AFTER CFO RESIGNS

Shares of Alkem Laboratories came under pressure in afternoon trade on Thursday after the pharmaceutical company announced the resignation of its Chief Financial Officer and Key Managerial Personnel, Nitin Agrawal. In an exchange filing dated September 24, the company said Agrawal had submitted his resignation on July 30, 2026, to pursue new professional opportunities. He will step down as CFO and cease to be a Senior Management Personnel of Alkem Laboratories with effect from September 30, 2026. In his resignation letter, Agrawal described his tenure as CFO of Alkem Laboratories as a "great honour" and said he would look back on his time with the company with gratitude. Agrawal highlighted several strategic initiatives he was involved in during his tenure, including building the company’s MedTech business from the ground up, the acquisition of Adroit, the creation of Alkem Wellness, the formation of a joint venture in Saudi Arabia and the acquisition of Bombay Ortho. He also said he had supported the monetisation of idle assets, including the Indore SEZ plant, improved returns from treasury income and helped implement the new UCPMP marketing guidelines in the domestic market. More recently, he was involved in leading the acquisition of Oculotech. Explaining his decision to step down, Agrawal said the move had not been easy but that he had chosen to pursue professional opportunities that were more closely aligned with his long-term professional and personal growth.

See More

Alkem Laboratories Shares Slip Over 2% After CFO Steps Down

Alkem Laboratories declined more than 2% in Thursday afternoon trade after the pharmaceutical company announced the resignation of its Chief Financial Officer and Key Managerial Personnel, Nitin Agrawal. The stock dropped as much as 2.04%, or ₹110.50, to ₹5,307 on the NSE around 12:44 pm. By 12:53 pm, it was trading at ₹5,318, down 1.84%. In an exchange filing on September 24, Alkem stated that Agrawal had resigned on July 30, 2026, to pursue new professional opportunities. He will remain in his role until September 30, 2026, to ensure a smooth transition. In his resignation letter, Agrawal described his tenure as “a great honour” and expressed gratitude for the experience. He thanked the board for entrusting him with key strategic initiatives, including building the MedTech business, acquiring Adroit, creating Alkem Wellness, forming a Saudi joint venture, and acquiring Bombay Ortho and Oculotech.

See More

Alkem rebounds from support, but cloud still caps it

has bounced sharply from the ₹5,100 to ₹5,160 support band, with price recovering to around ₹5,348. The rebound is notable because that lower zone has acted as support before, but the stock is still trading below a heavy Ichimoku resistance cluster. The business itself remains anchored in domestic branded formulations, chronic therapies and a meaningful US presence. That gives Alkem a relatively defensive earnings profile, but the chart is still in a transition phase rather than a clean uptrend. The Tenkan sits near ₹5,206, while the Kijun is around ₹5,293. Price has moved above both, which is the first positive sign. The bigger hurdle is the cloud, with resistance stretching roughly from ₹5,250 to ₹5,470 and a visible supply zone around ₹5,550 to ₹5,600. My reading is that the bounce has improved the setup, but confirmation is still missing. A sustained move above ₹5,470 would strengthen the case for a larger recovery toward ₹5,550 to ₹5,600. If the stock slips back below ₹5,200, the recent rebound would start to look like another failed attempt. For now, this is a recovery setup, not a confirmed breakout.

See More

Alkem Laboratories Launches Epilepsy Drug NeuCeno

Alkem Laboratories

announced on Wednesday, September 16, 2026, the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients, marking the drug's first introduction in India. About The Launch The company said an estimated 94 lakh people live with epilepsy in India, giving a sense of the addressable patient population for this therapy. NeuCeno is a once-daily oral treatment, available in strengths ranging from 12.5 mg to 200 mg tablets, allowing dosing to be tailored to individual patients over a titration period, which is typical for anti-seizure medications of this kind. Why This Launch Matters Bringing a novel molecule to market for the first time in a country gives a pharmaceutical company a period of relatively limited direct competition for that specific drug, at least until other companies introduce their own versions or generics become available. For Alkem, expanding into a specialised neurology therapy like this adds to its existing portfolio beyond its traditional strongholds. Business Context Alkem Laboratories is one of India's larger pharmaceutical companies, spanning branded generics, formulations, and active pharmaceutical ingredients, sold domestically and in markets including the United States. Market Backdrop The announcement comes on a day when broader Indian equity benchmarks snapped a two-day losing streak, with the Sensex closing 333 points higher and the Nifty50 up 99 points, driven mainly by gains in banking and financial services stocks. What To Watch Physician adoption rates for NeuCeno in the coming quarters, and how it's priced relative to existing anti-seizure medications available in the Indian market. This update is based on the company's own announcement. It is not investment advice.

See More

Alkem Labs Launches First Cenobamate Drug in India

: Alkem Laboratories has launched NeuCeno (cenobamate), a new anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. This marks the first launch of cenobamate in India, expanding Alkem’s presence in the CNS and specialty-care segment. The introduction of the therapy provides an additional treatment option for adult patients with partial-onset seizures and strengthens Alkem’s domestic product portfolio. The launch also gives the company an opportunity to establish a new specialty brand in an area of neurological care where treatment options continue to evolve. Commercial performance will depend on physician adoption, patient uptake and the company’s ability to build the brand in the Indian market. Overall, the launch represents a positive portfolio-expansion development for Alkem Laboratories. Stock Commentary – Alkem Laboratories ALKEM – POSITIVE (7/10): Launch of NeuCeno (cenobamate) marks the first introduction of this therapy in India and strengthens Alkem’s CNS portfolio. The new specialty product could provide an additional growth opportunity as physician and patient adoption develops.

See More

Alkem Launches Neuceno for Epilepsy Treatment

has launched Neuceno (cenobamate) in India for the treatment of partial-onset seizures in adult patients, marking the first launch of cenobamate in the Indian market, according to the company announcement. The product expands Alkem’s presence in the neurology/CNS segment, where the company already offers a broad portfolio of therapies. Neuceno is an oral, once-daily anti-seizure therapy available in multiple dosage strengths, providing flexibility for physicians to individualize treatment. Cenobamate is an established treatment for partial-onset seizures in adults; U.S. prescribing information describes once-daily dosing with gradual titration and maintenance dosing based on clinical response and tolerability. The launch is relevant because epilepsy management often requires long-term therapy and appropriate dose optimization. The availability of a new molecule in India could broaden treatment options for adult patients whose seizures require additional or alternative therapeutic approaches. Alkem has an established presence in CNS and neurology and operates a large India-focused commercial network, which can support the product’s reach among healthcare professionals. From a business perspective, the launch strengthens Alkem’s specialty and chronic-care portfolio and provides an opportunity to participate in the domestic market for newer anti-seizure therapies. However, the eventual commercial contribution will depend on physician adoption, pricing, reimbursement/accessibility, competition from existing anti-epileptic medicines and the pace of patient uptake. Cenobamate also carries important prescribing considerations, including gradual titration and safety warnings, meaning treatment should be initiated and adjusted under appropriate medical supervision.

See More